Bicara Therapeutics Inc. ... (BCAX)
NASDAQ: BCAX
· Real-Time Price · USD
11.19
0.69 (6.57%)
At close: Sep 24, 2025, 3:59 PM
11.41
1.97%
After-hours: Sep 24, 2025, 06:47 PM EDT
6.57% (1D)
| Bid | 10.01 |
| Market Cap | 610.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.67M |
| EPS (ttm) | -4.66 |
| PE Ratio (ttm) | -2.4 |
| Forward PE | -4.01 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 11.41 |
| Volume | 731,627 |
| Avg. Volume (20D) | 405,055 |
| Open | 10.56 |
| Previous Close | 10.50 |
| Day's Range | 10.51 - 11.46 |
| 52-Week Range | 7.80 - 28.09 |
| Beta | -1.41 |
| Ex-Dividend Date | n/a |
About BCAX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCAX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
-40.8%
Bicara Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
4 months ago
+7.33%
Bicara Therapeutics shares are trading lower after the company announced a publication of phase 1/1b trial data for ficerafusp alfa showing mixed results, with median survival still unreached and limited clarity on long-term efficacy.
